ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A Phase I clinical trial in the U.K. has left six volunteers in an intensive care unit. Boston-based Parexel was running the trial for TGN 1412, an immunomodulatory monoclonal antibody being developed by the German biopharmaceutical company TeGenero for the treatment of autoimmune/inflammatory diseases and hematooncological malignancies. The trial was the first time the drug was used in humans. "Such an adverse reaction occurs extremely rarely, and this is an unfortunate and unusual situation," says Herman Scholtz, head of Parexel International Clinical Pharmacology. The patients are being treated at Northwick Park Hospital, where the trials were being conducted. The U.K.'s Medicines & Healthcare Products Regulatory Agency has suspended the trials and promises an "exhaustive investigation."
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter